Estudios

Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC). Eur Respir J 2024; 63: 2301689 Only a half of people with bronchiectasis in Europe use airway clearance management. Use of and access to devices, mucoactive drugs and specialist chest physiotherapy appears to be limited in many European countries

Presenta: Dr. Felipe Cayupi

19 de junio 2024 16:00hrs / 17:15hrs

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med Vol 208, Iss 4, pp 406–416, Aug 15, 2023 Ensifentrine significantly improved lung function in both trials, with results supporting exacerbation rate and risk reduction in a broad COPD population and in addition to other classes of maintenance therapies

Presenta: Dr. Diego Gordillo

05 de junio 2024 16:00hrs / 17:15hrs

Long-Term Follow-Up of Interstitial Lung Abnormality: Implication in Follow-Up Strategy and Risk Thresholds. Am J Respir Crit Care Med Vol 208, Iss 8, pp 858–867, Oct 15, 2023 For individuals with initially detected ILA, follow up CT at 3-year intervals may be appropriate to monitor radiologic progression; however, those at high risk of adverse outcomes on the basis of the quantified extent of fibrotic ILA and the presence of honeycombing may benefit from shortening the interval for follow-up scans.

Presenta: Dr. Miljenko Lolas

27 de mayo 2024 16:00hrs / 17:15hrs

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer. N Engl J Med 2023;389:504-13 CONCLUSIONS: In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone

Presenta: Dr. Francisco Osses

22 de mayo 2024 16:00hrs / 17:15hrs

Anaerobic Antibiotic Coverage in Aspiration Pneumonia and the Associated Benefits and Harms A Retrospective Cohort Study. DOI: https://doi.org/10.1016/j.chest.2024.02.025 Extended anaerobic coverage likely is unnecessary in aspiration pneumonia because it is associated with no additional mortality benefit, only an increased risk of C. difficile colitis.

Presenta: Dra. Macarena Lagos

15 de mayo 2024 16:00hrs / 17:15hrs